MA53172A - Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 - Google Patents

Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1

Info

Publication number
MA53172A
MA53172A MA053172A MA53172A MA53172A MA 53172 A MA53172 A MA 53172A MA 053172 A MA053172 A MA 053172A MA 53172 A MA53172 A MA 53172A MA 53172 A MA53172 A MA 53172A
Authority
MA
Morocco
Prior art keywords
interleukin
activity inhibitors
sulfonimidamide
compounds
sulfonimidamide compounds
Prior art date
Application number
MA053172A
Other languages
English (en)
Inventor
Amogh Boloor
Sarah M Bronner
Christopher Mcbride
Richard M Pastor
Nadezda Sokolova
Steven Thomas Staben
Craig Stivala
Lynnie Lin Trzoss
Matthew Volgraf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA53172A publication Critical patent/MA53172A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA053172A 2018-07-20 2019-07-19 Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 MA53172A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862701313P 2018-07-20 2018-07-20

Publications (1)

Publication Number Publication Date
MA53172A true MA53172A (fr) 2021-05-26

Family

ID=67659954

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053172A MA53172A (fr) 2018-07-20 2019-07-19 Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1

Country Status (21)

Country Link
US (1) US20210253596A1 (fr)
EP (1) EP3823974A1 (fr)
JP (1) JP7320595B2 (fr)
KR (1) KR20210034596A (fr)
CN (1) CN112513048A (fr)
AR (1) AR115822A1 (fr)
AU (1) AU2019306658A1 (fr)
BR (1) BR112021001044A2 (fr)
CA (1) CA3105521A1 (fr)
CL (1) CL2021000153A1 (fr)
CO (1) CO2021001530A2 (fr)
CR (1) CR20210022A (fr)
IL (1) IL279256A (fr)
MA (1) MA53172A (fr)
MX (1) MX2021000780A (fr)
PE (1) PE20211811A1 (fr)
PH (1) PH12021500005A1 (fr)
SG (1) SG11202013062VA (fr)
TW (1) TWI825134B (fr)
UA (1) UA128558C2 (fr)
WO (1) WO2020018975A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201837021A (zh) 2017-01-23 2018-10-16 美商傑庫爾醫療股份有限公司 作為介白素-1活性抑制劑之化合物
CN117143042A (zh) 2017-07-24 2023-12-01 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
MX2021000660A (es) 2018-07-20 2021-03-25 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1.
CN113286784A (zh) * 2018-11-16 2021-08-20 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
JP2022518260A (ja) * 2019-01-23 2022-03-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物
EP3986879A1 (fr) 2019-06-21 2022-04-27 AC Immune SA 1,2-thiazoles et 1,2 thiazines fusionnés qui agissent en tant que modulateurs de nl3p3
WO2021002887A1 (fr) * 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Antagonistes de nlrp3 ciblant l'intestin et leur utilisation en thérapie
CN112851607A (zh) * 2019-11-12 2021-05-28 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
CN115461120A (zh) * 2020-01-22 2022-12-09 豪夫迈·罗氏有限公司 作为nlrp3调节剂的磺酰亚胺酰胺化合物
IL296488A (en) 2020-03-16 2022-11-01 Zomagen Biosciences Ltd nlrp3 modulators
JP2023522016A (ja) 2020-04-15 2023-05-26 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｌｒｐ３インフラマソーム経路の阻害剤としてのピラゾロ［１，５－ｄ］［１，２，４］トリアジン－５（４ｈ）－アセトアミド
WO2021209539A1 (fr) 2020-04-15 2021-10-21 Janssen Pharmaceutica Nv Pyrrolo[1,2-d][1,2,4]triazine-2-yl-acétamides utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3
MX2022013323A (es) 2020-04-23 2022-11-30 Janssen Pharmaceutica Nv Compuestos triciclicos como inhibidores de nlrp3.
US20230183249A1 (en) 2020-04-30 2023-06-15 Janssen Pharmaceutica Nv New triazinoindole compounds
US20230202989A1 (en) 2020-05-28 2023-06-29 Janssen Pharmaceutica Nv Compounds
EP4168395A1 (fr) 2020-06-19 2023-04-26 AC Immune SA Dérivés de dihydrooxazole et de thiourée modulant la voie inflammatoire nlrp3
AU2021346847A1 (en) 2020-09-24 2023-06-08 Janssen Pharmaceutica Nv New compounds
EP3974415A1 (fr) 2020-09-24 2022-03-30 Janssen Pharmaceutica NV Nouveaux composés
CN114539256B (zh) * 2020-11-20 2024-02-02 上海拓界生物医药科技有限公司 三环化合物及其医药用途
AU2022231379A1 (en) 2021-03-04 2023-10-19 Janssen Pharmaceutica Nv 4-alkoxy-6-oxo-pyridazine derivatives modulating nlrp3
US20240174670A1 (en) 2021-03-04 2024-05-30 Janssen Pharmaceutica Nv 4-amino-6-oxo-pyridazine derivatives modulating nlrp3
CA3212725A1 (fr) 2021-04-29 2022-11-03 Daniel Oehlrich Derives de phtalazinone en tant qu'inhibiteurs d'inflammation de nlrp3
TW202246230A (zh) * 2021-05-10 2022-12-01 大陸商成都百裕製藥股份有限公司 醯胺衍生物及其應用
CN116917282A (zh) * 2021-05-10 2023-10-20 成都百裕制药股份有限公司 酰胺衍生物及其应用
EP4363418A1 (fr) 2021-07-01 2024-05-08 JANSSEN Pharmaceutica NV Acétamides 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl
JP2024528656A (ja) * 2021-07-19 2024-07-30 ジェネンテック， インコーポレイテッド スルホンイミドアミド化合物およびその使用
CN118541366A (zh) 2021-12-22 2024-08-23 Ac免疫有限公司 二氢噁唑衍生物化合物
WO2024010772A1 (fr) * 2022-07-06 2024-01-11 Kodiak Sciences Inc. Inhibiteurs de nlrp3
WO2024013395A1 (fr) 2022-07-14 2024-01-18 Ac Immune Sa Dérivés de pyrrolotriazine et d'imidazotriazine utilisés en tant que modulateurs de la voie de l'inflammasome nlrp3
WO2024023266A1 (fr) 2022-07-28 2024-02-01 Ac Immune Sa Nouveaux composés
US20240124451A1 (en) 2022-09-23 2024-04-18 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47440B1 (fr) 2015-02-16 2021-08-31 The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv Sulfonylurées, composés apparentés, et leur utilisation
TW201837021A (zh) 2017-01-23 2018-10-16 美商傑庫爾醫療股份有限公司 作為介白素-1活性抑制劑之化合物
CN117143042A (zh) * 2017-07-24 2023-12-01 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
US11623922B2 (en) * 2017-10-03 2023-04-11 Inflazome Limited Compounds

Also Published As

Publication number Publication date
BR112021001044A2 (pt) 2021-04-13
KR20210034596A (ko) 2021-03-30
EP3823974A1 (fr) 2021-05-26
WO2020018975A1 (fr) 2020-01-23
CN112513048A (zh) 2021-03-16
SG11202013062VA (en) 2021-02-25
TWI825134B (zh) 2023-12-11
PH12021500005A1 (en) 2021-09-13
CR20210022A (es) 2021-02-18
JP2021532101A (ja) 2021-11-25
JP7320595B2 (ja) 2023-08-03
UA128558C2 (uk) 2024-08-14
IL279256A (en) 2021-01-31
PE20211811A1 (es) 2021-09-14
CA3105521A1 (fr) 2020-01-23
AU2019306658A1 (en) 2021-01-07
MX2021000780A (es) 2021-03-31
CO2021001530A2 (es) 2021-03-08
AR115822A1 (es) 2021-03-03
TW202016078A (zh) 2020-05-01
US20210253596A1 (en) 2021-08-19
CL2021000153A1 (es) 2021-07-09

Similar Documents

Publication Publication Date Title
MA53172A (fr) Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
MA53170A (fr) Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1
MA53395A (fr) Composés hétérobicycliques pour inhiber l'activité de shp2
MA47308A (fr) Composés chimiques comme inhibiteurs de l'activité interleukine-1
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA52421A (fr) Composés pharmaceutiques
MA48765A (fr) Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub
MA52942A (fr) Composés inhibiteurs d'oga
MA44734A (fr) Composés et compositions destinés au traitement d'états associés à une activité de nlrp
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA52939A (fr) Composés inhibiteurs d'oga
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA52948A (fr) Composés
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA51669A (fr) Composés
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA53003A (fr) Composés
MA42488A (fr) Composés, compositions et procédés pour augmenter l'activité du cftr